SCHEMBL2961877

SCHEMBL2961877

CCCc1ccc(OC)c(-c2csc(NC(=O)NN3CCN(CC(=O)N4CCCC4)CC3)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 12/20 0.45
MEN1 O00255 10/20 0.45
MAPT P10636 5/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KCNQ1 P51787 1/20 0.42
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
MAPK1 P28482 1/20 0.39
NPC1 O15118 1/20 0.39
ACHE P22303 1/20 0.39
F2 P00734 1/20 0.39
F10 P00742 1/20 0.39
LMNA P02545 1/20 0.39
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
RECQL P46063 1/20 0.38
SIRT5 Q9NXA8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950908 0.97 KMT2A (0.45) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL13198962 0.89 KMT2A (0.46) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL2947767 0.88 KMT2A (0.44) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL2957637 0.88 KMT2A (0.45) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL13198979 0.87 KMT2A (0.46) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL2960279 0.87 KMT2A (0.38) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL2961641 0.85 KMT2A (0.45) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL2957660 0.85 CPT1A (0.41) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL2961585 0.84 ROCK1 (0.47) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL13198963 0.84 KMT2A (0.45) KMT2AMEN1MAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771425-B1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-05-14 EP claimed
US-20070179126-A1 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-08-02 US claimed
US-7767681-B2 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-08-03 US disclosed
EP-1771425-B1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-05-14 EP disclosed
US-20070179126-A1 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-08-02 US disclosed
EP-1771425-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-04-11 EP disclosed
WO-2006016039-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179126-A1 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof UGT2B7, PKD2, CYP2C19 KMT2A 1446/4885MEN1 990/4885MAPT 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.